Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

News

November 10, 2022
PRESS RELEASE: A new research paper was published in Oncotarget on November 2, 2022, entitled, “MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.” continue reading »

Oncotarget | Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study

News

November 9, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on November 2, 2022, entitled, “Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study.” continue reading »

Oncotarget | Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer

News

November 8, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on November 2, 2022, entitled, “Predictive molecular biomarkers for determining neoadjuvant chemosensitivity in muscle invasive bladder cancer.” continue reading »

Oncotarget | The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells

News

November 7, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on October 20, 2022, entitled, “The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells.” continue reading »

Oncotarget | Nectin-4 is widely expressed in head and neck squamous cell carcinoma

Oncotarget

November 3, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on October 20, 2022, entitled, “Nectin-4 is widely expressed in head and neck squamous cell carcinoma.” continue reading »